Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339133 | 0.99 | SGMS2 (0.54) | KMT2AMEN1ALDH1A1SGMS2MAOB | |
| SCHEMBL338498 | 0.98 | MEN1 (0.50) | KMT2AMEN1ALDH1A1SGMS2MAOB | |
| SCHEMBL339006 | 0.96 | BRD4 (0.47) | KMT2AMEN1ALDH1A1SGMS2MAOB | |
| SCHEMBL337855 | 0.83 | IDH1 (0.49) | KMT2AMEN1ALDH1A1MAOBBRD4 | |
| SCHEMBL13395924 | 0.81 | BRD4 (0.50) | ALDH1A1MAOBBRD4NPC1RAB9A | |
| SCHEMBL338697 | 0.80 | IDH1 (0.50) | KMT2AMEN1ALDH1A1MAOBHTT | |
| SCHEMBL338935 | 0.78 | IDH1 (0.48) | KMT2AMEN1ALDH1A1HTTNPC1 | |
| SCHEMBL338494 | 0.78 | KMT2A (0.52) | KMT2AMEN1ALDH1A1SGMS2MAOB | |
| SCHEMBL339140 | 0.77 | SGMS2 (0.53) | KMT2AMEN1ALDH1A1SGMS2MAOB | |
| SCHEMBL2984201 | 0.77 | MMP3 (0.72) | KMT2AMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687298-B1 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | APOTEX INC (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-8097624-B2 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. (CA) | 2012-01-17 | — | — | US | disclosed |
| US-20090170850-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. | 2009-07-02 | — | — | US | disclosed |
| CN-100448873-C | Cycloalkyl derivatives of 3-hydroxy-4-pyridones | APOTEX INC (CA) | 2009-01-07 | — | — | CN | disclosed |
| US-7410985-B2 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. (CA) | 2008-08-12 | — | — | US | disclosed |
| US-20070082904-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention | APOTEX INC. (CA) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170850-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | HAMP, C1S, C1R | KMT2A 3229/4885MEN1 883/4885ALDH1A1 1709/4885 |
| US-20070082904-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention | HAMP, C1S, SLC40A1 | KMT2A 4366/4885MEN1 640/4885ALDH1A1 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.